bit.bio welcomes Anthony Browne MP to open Cambridge headquarters


06-09-2021
South Cambridgeshire MP Anthony Browne cut the ribbon at the official opening of the facilities. Left-right Derek Jones, CEO of Babraham Research Campus, Mark Kotter founder and CEO bit.bio, Anthony Browne, MP South Cambridgeshire and Florian Schuster, co-founder bit.bio.

South Cambridgeshire MP Anthony Browne has officially opened the labs and office space of Cambridge-based synthetic biology start-up bit.bio.

He was welcomed by bit.bio founder and CEO Mark Kotter, co-founder Florian Schuster and CEO of Babraham Research Campus, Derek Jones. They toured the facilities and bit.bio scientists explained its opti-ox™ technology and showcased its products. After the ribbon-cutting ceremony, Anthony enjoyed refreshments and conversations with the bit.bio team.

bit.bio is a synthetic biology company which aims to revolutionise medicine by developing an industrial scale supply of every type of human cell for research and cell therapies. Such therapies could be the key to treating many complex conditions including Alzheimer’s and Parkinson’s.

Anthony Browne MP said: “Their facilities are hugely impressive, and they are pushing the boundaries of what is possible at the cutting edge of biomedical research! I wish them every success and look forward to their continuing growth here in South Cambs.”

Image: South Cambridgeshire MP Anthony Browne cut the ribbon at the official opening of the facilities. Left-right Derek Jones, CEO of Babraham Research Campus, Mark Kotter founder and CEO bit.bio, Anthony Browne, MP South Cambridgeshire and Florian Schuster, co-founder bit.bio.

 

 

bit.bio’s mission is to apply the principles of data science to biology to code cells for the wellbeing of humanity. Its proprietary technology, opti-ox, enables highly efficient and consistent reprogramming of human cells for use in research, drug discovery, and cell therapy. This scalable platform for the production of human cells is also the basis for a new generation of cell and tissue therapies.

bit.bio